Toll-like receptors 2, 4, and 9 expressions over the entire clinical and immunopathological spectrum of American cutaneous leishmaniasis due to Leishmania (V.) braziliensis and Leishmania (L.) amazonensis

Leishmania (V.) braziliensis and Leishmania(L.) amazonensis are the most pathogenic agents of American Cutaneous Leishmaniasis in Brazil, causing a wide spectrum of clinical and immunopathological manifestations, including: localized cutaneous leishmaniasis (LCLDTH+/++), borderline disseminated cutaneous leishmaniasis (BDCLDTH±), anergic diffuse cutaneous leishmaniasis (ADCLDTH-), and mucosal leishmaniasis (MLDTH++++). It has recently been demonstrated, however, that while L. (V.) braziliensis shows a clear potential to advance the infection from central LCL (a moderate T-cell hypersensitivity form) towards ML (the highest T-cell hypersensitivity pole), L. (L.) amazonensis drives the infection in the opposite direction to ADCL (the lowest T-cell hypersensitivity pole). This study evaluated by immunohistochemistry the expression of Toll-like receptors (TLRs) 2, 4, and 9 and their relationships with CD4 and CD8 T-cells, and TNF-α, IL-10, and TGF-β cytokines in that disease spectrum. Biopsies of skin and mucosal lesions from 43 patients were examined: 6 cases of ADCL, 5 of BDCL, and 11 of LCL caused byL. (L.) amazonensis; as well as 10 cases of LCL, 4 of BDCL, and 6 of ML caused byL. (V.) braziliensis. CD4+ T-cells demonstrated their highest expression in ML and, in contrast, their lowest in ADCL. CD8+ T-cells also showed their lowest expression in ADCL as compared to the other forms of the disease. TNF-α+showed increased expression from ADCL to ML, while IL-10+and TGF-β+ showed increased expression in the opposite direction, from ML to ADCL. With regards to TLR2, 4, and 9 expressions, strong interactions of TLR2 and 4 with clinical forms associated with L. (V.) braziliensis were observed, while TLR9, in contrast, showed a strong interaction with clinical forms linked to L. (L.) amazonensis. These findings strongly suggest the ability of L. (V.) braziliensis and L. (L.) amazonensis to interact with those TLRs to promote a dichotomous T-cell immune response in ACL.


Introduction
American cutaneous leishmaniasis (ACL) is a parasitic protozoan disease caused by different species of the genus Leishmania that are widely distributed throughout Latin America [1]. At present, there are at least fifteen recognized species of Leishmania within the subgenera Leishmania, Viannia, and Mundinia that may give rise to ACL [2]. In Brazil, where seven of these species are found, Leishmnia (V.) braziliensis and Leishmania (L.) amazonensisshowthe highest pathogenic potential for humans, being responsible for a wide spectrum of disease, including: localized cutaneous leishmaniasis (LCL), borderline disseminated cutaneous leishmaniasis (BDCL), anergic diffuse cutaneous leishmaniasis (ADCL), and mucosal leishmaniasis (ML) [3].
The immunopathogenesis of ACL has gained great interest due to the complex interactions of Leishmania species with human T-cell immune responses. There have been recent findings concerning the clinical-immunopathological spectrum of ACL caused by L. (V.) braziliensis and L. (L.) amazonensis that have helped clarify the immunopathogenic capacities of those two Leishmania species. It has been shown that L. (V.) braziliensis and L. (L.) amazonensis may produce not only LCL (the most frequent form of the disease occupying the center of that spectrum, with moderate T-cell hypersensitivity), but principally ML andADCL, the most severe forms occupying the extreme pathogenicity poles of that spectrum; i.e., the highest and lowest T-cell hypersensitivity, respectively. Additionally, those Leishmania species may also produce BDCL, an intermediary form showing partial inhibition of T-cell hypersensitivity between the central LCL and the two polar forms, ML and ADCL, which can occupy both sides of that spectrum (i.e., BDCL may be produced either by L. (V.) spp. or L. (L.) spp.) [4]. It should also be noted that the immunopathogenic abilities of L. (V.) braziliensis and L. (L.) amazonensis have been confirmed in experimental BALB/c mice model-which have shown that those Leishmania species are able to modulate differential expressions of dendritic cells and T-cell immune responses [5].
With regards to the immunopathology of ACL, there is recent evidence of the involvement of CD4 + (Th1, Th2, Th17 and Treg-Foxp3+CD4+CD25+) and CD8 + T-cell subset profiles, as well as some cytokines produced by those cells, such as, IFN-γ, IL-4, IL-10, and TGF-β, as well as iNOS expression over the entire clinical-immunopathological spectrum of the disease caused by L. (V.) braziliensis and L. (L.) amazonensis. In that respect, the pivotal role of CD4 + / Th1-type immune response associated to significant expression of CD8 + T-cells, IFN-γ, and iNOS should be emphasized in determining resistance against leishmanial infections. That is, in general, the immune response profile found in most clinical forms of ACL (LCL, BDCL and ML)-with exception of ADCL, which is characterized by a strong CD4 + /Th2-type immune response associated with low levels of CD8 + T-cells and high expression of IL-4, IL-10 and TGF-β cytokines. Treg(Foxp3)-cells were also detected at low to moderate levels in most clinical forms of ACL (LCL, BDCL and ML), but at higher levels in ADCL [6].
The essential role of Toll-like receptors (TLRs) in the development of the innate and adaptive immune responses against different types of invasive microorganisms should not be forgotten. TLRs are transmembrane glycoproteins that lend high levels of specificity to innate immune responses by recognizing every type of invasive microorganism that may infect humans. TLRs are principally found either within the plasma membrane or within the internal membranes of macrophages, DCs, and NK cells. They may also be found, with lower expression, in T and B lymphocytes [7,8]. Ten TLRs have so far been described in humans (TLR1-10) that can be separated into two groups, depending upon their localization within cells: i) TLR1, 2, 4, 5 and 6 encountered on the plasmatic surface, with intracellular protein domains of the TIR type (MyD88, TIRAP, TRIF and TRAM), and, ii) TLR3, 7, 8 and 9 that reside in internal membranes, such as lysosomes, but without specific extracellular domains; little is currently known about TLR10 [9]. Each TLR receptor has its own self-signaling pathway that promotes specific biological responses leading to the sensitization of genes involved in host defenses against microorganisms. Thus, after recognition of a specific antigen, TLRs trigger NF-κB to reach the nucleus, allowing the transcription and production of pro-inflammatory cytokines. This process usually requires the intervention of an adaptor protein having the TIR repeated domain, with MyD88 being the molecule most commonly used by TLRs (with exception of TLR3) [10].
In terms of Leishmania sp. infections, there is in vitro and in vivo evidence demonstrating the crucial role of TLRs in the development of protective immune responses against those infections, and recent studies have largely concentrated on TLR2, 4, and 9 [11]. Additionally, the indispensable role ofMyD88 in the generation of protective immunity to L. (V.) braziliensis-infections in mice should be mentioned here, with TLR2 appearing to have a regulatory role during infection [12]. When TLR2 and 4 expressions were investigated in LCL caused by the same Leishmania species, however, a higher expression of TLR2 as compared to that of TLR4 was observed during the active disease (mainly in macrophages)-although without correlations with cytokine titers or number of cells [13]. The role of TLR2 was also examined in two different clinical forms of ACL (LCL and ADCL) caused by L. (L.) mexicana in Mexico [14,15]-a parasite closely related to L. (L.) amazonensis in Brazil [4]. In the first approach, the ability of TLR2 ligands to restore the effector function of exhausted CD8 + T-cells from ADCL patients against L. (L.) mexicana-infected macrophages was demonstrated [14]. In the second approach, a higher down-regulation of the innate immune response-genes in NK cells from severe ADCL as compared to those from LCL, especially those related to TLR2 and JAK/STAT signaling pathways, was confirmed [15]. The role of TLR9 was also investigated in LCL due to L. (V.) braziliensis showing a strong association with granuloma in the dermis of cutaneous lesions of patients, principally in macrophage cells [16]. However, although TLR9 was associated with granuloma in the dermis of cutaneous lesions of patients with LCL caused by L. (V.) braziliensis, experiments with TLR9_/_mice infected with the same parasite species showed that TLR9 signaling is important for early control of lesion development and parasite burdens, but is dispensable for the differentiation of Th1 cells secreting IFN-γ [17]. In other experiments regarding the roles of MyD88-or TLR9-dependent signaling pathways in mice infected by L. (V.) guyanensis, the principal role of both MyD88 and TLR9 in the development of Th1-dependent healing responses against L. (V.) guyanensis was demonstrated [18].
Thus, taking into account the above comments, we decided to investigate TLR2, 4, and 9 expressions over theentire clinical-immunopathological spectrum of ACL caused by L. (V.) braziliensis and L. (L.) amazonensis to better understand the immunopathogenesis of the disease. The present results provided strong evidence for associating TLR2 and 4 with beneficial T-cell immune response in LCL and BDCL caused either by L. (V.) braziliensis or L. (L.) amazonensis. In contrast, TLR9 showed strong association with the inhibition of T-cell immune responses in ACL forms caused by L. (L.) amazonensis, principally the subpolar BDCL and polar ADCL forms.

Study design
The Present study was of the cross-sectional type, in which we analyzed skin and/or mucosal samples (biopsies) from patients with ACL caused by L. (V.) braziliensis (L.b) and L. (L.) amazonensis (L.a) by immunohistochemistry for the expression of TLR2, 4, and 9 as well as CD4 and CD8 T-cells and the cytokines TNF-α, IL-10 and TGF-β in the immunopathogenesis of the different clinical forms of that disease (LCL/L.b-L.a, BDCL/L.b-L.a, ML/L.b and ADCL/L.a).

Clinical samples
Biopsies of skin and mucosal lesions from 43 patients were examined: six cases of ADCL, five of BDCL, and eleven of LCL caused by L. (L.) amazonensis; ten cases of LCL, four of BDCL, and six of ML caused by L. (V.) braziliensis. Other data on age, gender, time and the type of lesion, and the DTH skin reaction of the patients are presented in Table 1. Patients diagnosed parasitologically and/or immunologically (DTH) with ACL and treatment-naïve were selected for the present study. The patients were examined in the ambulatory of the "Prof. Dr. Ralph Lainson Leishmaniasis Laboratory" at the Evandro Chagas Institute (SVS-MS), Ananindeua, Pará State, Brazil, during the period between January/2012 and December/2015. All of the patients were submitted to clinical and laboratory evaluations for ACL diagnosis and all of the confirmed clinical cases received specific treatments for that disease. However, as all of the six ADCL patients had been unsuccessfully treated for more than ten years in our ambulatory, all had already experienced different therapeutic schemes with meglumine antimoniate, pentamidine isetionate, or Amphotericin B. All of the clinical and laboratory procedures to confirm ACL diagnosis were performed as described in earlier works [19,20].

Isolation and identification of L. (V.) braziliensis and L. (L.) amazonensis from cutaneous and mucosal lesions of the patients
The process for isolating Leishmania spp. from patients suffering from ACL was published previously [19,20]. The characterization of Leishmania species was performed using PCR-RFLP , and another of the hsp70 gene, whose products were purified and cleaved using HaeIII restriction enzyme (Invitrogen-Carsbad, Califórnia, USA); both products were used to detect polymorphisms and then compared with reference strains of the subgenera Viannia and Leishmania known to act as ACL agents in northern Brazil [21][22][23].

Immunohistochemical analyses
Processing: A fragment of each biopsy was fixed in 10% neutral formaldehyde and embedded in paraffin. Histological sections (4 μm) were made and collected on biotinylated slides (SIGMA), diaphonized in two baths of cold xylene (20 and 10 minutes each), and then hydrated in a decreasing ethanol series (100%, 90%, 80% and 70%) lasting 2 min. each, being subsequently immersed in a pH 7.4 PBS (Phosphate Buffered Saline) solution for 5 min.

Immunohistochemical reactions
This process was undertaken following a previously described technique, with modifications. We used the same immunohistochemical protocol for the immunological markers in the present study, except for the TLRs, which were performed during differential steps designed for double marking (varying only in the primary antibody step, its dilution, and antigenic recuperation). We employed the labeled Streptavidin-biotin method, LSAB-HRP (Dako-Carpinteria, California, USA), in which a secondary biotinylated antibody reacts with various molecules of streptavidin conjugated to peroxidase [3,24]. S1 Table lists the primary antibodies used, their codes, dilutions, and the treatments utilized for antigen exposition.

Immunohistochemical staining of CD4 and CD8 T-cells
Incubations of the histological sections against CD4 and CD8 T-cells diluted in PBS with 1% BSA overnight at 4˚C were performed under the same conditions described above for the primary antibodies (S1 Table) [3].

Immunostaining of TNF-α, IL-10 and TGF-βcytokines
After removing the paraffin, hydrating the tissue sections, blocking endogenous peroxidase, and antigen recuperation using 10 mM citrate buffer (pH 6.0), as described above, the slides were washed in distilled water for 5 min. and then in PBS buffer containing 0.1% saponin for 10 min., being subsequently washed in distilled water and PBS (pH 7.4) for 5 min. each. Nonspecific tissue proteins were then blocked by incubation in a 10% skimmed milk solution (Molico 1 , Nestle) for 30 min. at room temperature. The slides were subsequently incubated overnight (at 4˚C) with the primary antibodies anti-TNF-α, anti-IL-10, and anti-TGF-β diluted in 1% BSA. The application reaction was performed using a LSAB-HRP kit (Dako-Carpinteria, California, USA), and the visualization reactions as well as subsequent steps were performed as previously described [24].
Double immunohistochemical staining for CD68 macrophages expressing TLR2, 4, and 9 Double immunohistochemical staining was used to verify the expression of TLR2, 4, and 9 on CD68+ macrophages. The protocol utilized for this reaction followed Tuon et al. [16], with some adaptations. These reactions are based on the same steps as the conventional immunohistochemical reactions already described, with few modifications. To investigate CD68+ macrophages, antigen exposure was performed in a Pascal pan at 95˚C for 20 min. in 10 mM citrate buffer (pH 6.0). The slides were then maintained at room temperature for 20 min. followed by the immunohistochemical protocol and visualization with DAB. After visualization, in a second step, the sections were washed in distilled water and PBS (pH 7.4) for 5 min. each, and then incubated with goat primary anti-TLR2 (SC 8689), anti-TLR4 (SC 8694), and anti-TLR9 (SC 13215) antibodies for 12 hours at 4˚C. The following step involved the exposure of the sections to the reagents of the LSAB + System-AP kit (Dako-Carpinteria, California, USA, code K0689) conjugated with a ready-to-use polymer of alkaline phosphatase in a humid chamber for 30 min. at 37˚C. The slides were subsequently washed in PBS (pH 7.4) and the linkage sites visualized with Liquid Permanent Red(Dako-Carpinteria, California, USA, code K0640).
The sections were subsequently washed in distilled water and PBS, stained with hematoxylin Harris for proximately 1 min., washed in distilled water, dehydrated in an ethanol series (70%, 80%, 90%, and absolute), diaphonized in xylene, and left to dry at room temperature. The sections were then mounted in Entellan resin.

Determining cell immunostaining density
In analyzing the immunostaining of the different cell phenotypes and cells expressing cytokines, the brown staining of their cytoplasm was considered a positive identification. Double immunohistochemical staining considered macrophage cells showing brown staining with colocalized TLR stained red as demonstrating TLR expression [16].
The immunostained cells were counted using an image analysis system (Axioskop 2 plus Zeiss) coupled to a microcomputer running the AxioVision 4.0 program. We photographed 10 fields of each histological section under a 40x objective, and the immunostained cells were counted using Imaje J software [25]. The mean numbers of marked cells per field were calculated and cell population densities were determined from the ratios of the marked cells per area (μm 2 ), which are presented here in mm 2 .

Ethics approval
This study was approved by the Ethics Committee in Human Research of the Evandro Chagas Institute (Surveillance Secretary of Health, Ministry of Health, Brazil) and Brazil Platform, under protocol number 102.885/2012. All patients enrolled in this study were informed about the study and signed a free-consent form in accordance with the principles of the Declaration of Helsinki.

Statistical analysis
The data were expressed as the means ± standard deviations. The parametric ANOVA test with the Tukey post-test was used to compare the quantitative values of each of the cell phenotypes (CD4 and CD8 T-cells), cytokines (TNF-α, TGF-β and IL-10), and the TLR2, 4, and 9 of the different clinical forms of ACL caused by L. (V.) braziliensis or L. (L.) amazonensis. The correlations of the expression of TLR2, 4, and 9 with the expression of CD4 + and CD8 + T-cells, as well as the cytokines (TNF-α + , TGF-β + and IL-10 + ) were performed using the Pearson correlation index. The results were considered significant when the probability of a significant error was less than 0.05 (p< 0.05). All of the statistical procedures were performed using Graph Pad Prism version 4.0 for Windows software (Graph Pad Software, San Diego, CA).

CD4 + and CD8 + T-cells densities among different clinical forms of ACL caused by L. (V.) braziliensis and L. (L.) amazonensis
With regards to CD4 + T-cell densities in the relative spectrum of ACL caused by L. (L.) amazonensis, there were no differences (p> 0.05) between the central form LCL (1465 ± 194.3 cells/ mm 2 ) and the subpolar BDCL form (1198 ± 84.2 cells/mm 2 ), although both clinical forms showed higher cell densities (p< 0.05) than the polar form ADCL (394 ± 159.3 cells/mm 2 ): LCL/BDCL > ADCL. It is also important to note that the ADCL form showed the lowest CD4 + T-cell density (p< 0.05) when compared to the other clinical forms of ACL. When the CD4 + T-cell densities were examined in terms of the relative spectrum of ACL caused by L. (V.) braziliensis, we observed a progressive and significant increase (p< 0.05) starting with the central LCL form (736 ± 134.9 cells/mm 2 ) towards the BDCL form (1696 ± 105.6 cells/mm 2 ) up to the ML form (2068 ± 245.0 cells/mm 2 ), with significant differences (p< 0.05) between them: LCL < BDCL < ML. As such, it could be observed that CD4 + T-cell density in the ML form was greater (p< 0.05) than any of the other clinical forms of ACL, whether caused by L.

Discussion
This is the first study undertaken in Brazil (more precisely, in the Brazilian Amazon) that analyzed the involvement of TLR2, 4, and 9 within the context of the entire clinical-immunopathological spectrum of ACL caused by the two Leishmania species with the greatest pathogenic potential for humans [L.  Toll-like receptors 2, 4, and 9 in American cutaneous leishmaniasis  Toll-like receptors 2, 4, and 9 in American cutaneous leishmaniasis CD4 + and CD8 + T-cells, and TNF-α + , IL-10 + and TGF-β + cytokines, aiming to better understand the immunopathogenesis and/or the immunopathology of that disease.
Although the roles of TLR2, 4, and 9 were the major interest of the present work, we could not fail to also consider the importance of other immunological factors, such as CD4 + and CD8 + T-cells, and the TNF-α + , IL-10 + and TGF-β + cytokines that take part in the T-cell immune responses against ACL. In this way, despite there have been some earlier research concerning the participation of CD4 + and CD8 + T-cells in the immunopathogenesis of ACL, no agreement has existed about what cell types are most well-represented in the cell infiltrates found in cutaneous lesions of that disease [26][27][28][29][30][31][32]. Thus, in the present work, as well as in prior research by our group [3,19], a higher expression of CD8 + over CD4  [33][34][35][36], or ii) a regulatory effect through the production of TGF-β and IL-10 cytokines in the presence of high parasite loads during infection by L. (L.) amazonensis [14]. There was also a greater expression of CD4 + T-cells in the polar ML/L.b form (hyper-reactivity cellular pole), precisely the clinical form with the highest expression of DTH (++++) and T-cell reactivity, as well as with significant expressions of IFN-γ + and TNF-α + , characterizing a typical CD4 + /Th1-type immune response [3,4]. Additionally, there were low expressions of both CD4 + and CD8 + T-cells in the polar ADCL/L.a form (hypo-reactivity cellular pole), although with high expression of CD8 + T-cells (with twice the expression of CD4 + Tcells), which reinforces the determinant role of the CD4 + T-cell response in the definition of Tcell immune response profile against infection, whether of resistance (CD4 + /Th1) or susceptibility (CD4 + /Th2) to infection. This certainly influences ACL evolution and may explain the development of clinical polar forms of that disease, such as ML/L.b (with a typical CD4 + / Th1-type immune response) and ADCL/L.a (with typical CD4 + /Th2-type immune response) [3,4,6]. Summarizing then, CD8 + T-cells appear to play dual role in the immunopathology of ACL depending on the antigenic environment where those cells are interacting, i.e., in cases of infection by L. (V.)braziliensis their cytotoxic action (via NLRP3 inflammasome activation or IL-1β production) may result in exacerbation of pathology [35,36], or in cases of infection by L. (L.) amazonensistheir regulatory action (via TGF-β and IL-10) may promote dissemination of infection [14].
With regards to the involvement of pro-inflammatory TNF-α + and the two regulatory TGF-β + and IL-10 + cytokines, the almost dichotomous behavior of these cytokines within the spectrum of ACL caused by L.  [4][5][6]. Within that context, the only exceptional situation arises in terms of the BDCL form caused by L. (V.)braziliensis, in which TNF-α + expression was lower than TGF-β + or IL-10 + expression-exactly in the clinical form that occurs with partial inhibition of the T-cell immune response (DTH +/-), thus facilitating infection dissemination [3,19]. This suggests that in individuals with less immunological competence (CD4 + /Th1<Th2) and/or who are overloaded with infectious metacyclic promastigotes forms, the parasite can escape from the protective immune response and multiply in an uncontrolled fashion and disseminates to other skin areas and/or the nasopharyngeal mucosa [4].
Based on the above comments, the generalization of the functional roles of some cytokines, such as the TNF-α + , must be considered with a certain caution as it is generally regarded as a pro-inflammatory cytokine with a pivotal role in macrophage activation and parasite control [37,38]. In that respect, it should be mentioned that the use of TNF-α + antagonists in asymptomatic individuals can promote the reactivation of infection by Leishmania sp. and the emergence of clinical signs of leishmaniasis-thus confirming the protective role of TNF-α + [39,40]. However, when TNF-α + expression was examined within the context of ACL caused by L. (V.) braziliensis or L. (L.) amazonensis, a weak expression of that cytokine on the associated spectrum side with L. (L.) amazonensis was noted; a strong TNF-α + expression was noted, however, in terms of the disease spectrum associated with L. (V.)braziliensis. This suggests that the functional activity of that cytokine is significantly influenced by its antigenic environment-that is, the parasite species involved [L. In that respect, some in vitro studies have indicated that the interactions of TLRs with different Leishmania species may lead to different immune responses [47]. Those  In that way, our results also revealed a high expression of TFN-α + which corroborates previous evidence indicating that the immune response on that side of the disease spectrum is predominantly of the CD4 + /Th1-type [3,4]. It should also be emphasized that the negative correlation between TLR4 + and TNF-α + in the polar ML form caused by L. (V.) braziliensis appears to reflect the strong expression of the CD4 + /Th1-type immune response characteristic of that form of the disease.
The limited expression of TLR2 and 4 on the disease spectrum pole relative to clinical forms caused by L. (L.) amazonensis (which showed strong TGF-β + and IL-10 + expressions) appears to demonstrate that the immune response in that direction has a clear CD4 + /Th2-type profile [3,4]. As such, and based on previous observations indicating that the parasites possess mechanisms capable of modulating the inflammatory responses induced by TLRs [47,48], the concept presented here is that the interactions of TLR2 and 4 with L. (V.) braziliensis seem to be related to a beneficial T-cell immune response. Corroborating that interpretation, the negative correlation between TLR2 + andTGF-β + in the central LCL form caused by L. (V.) braziliensis suggests a likely protector effect of TLR2 + by inhibiting TGF-β + .
It should also be noted that TLR2 and 4 have been considered pivotal actors in the immune response of ACL, as it has been shown in in vitro trials that infections caused by L. (V.) braziliensis and L. (V.) panamensis induce increased expression of those macrophage receptors in humans-indicating their participation in the innate immune response to ACL caused by those Leishmania species [49]. Similarly, and corroborating the results of the present work, it has been demonstrated that TLR2 expression in cutaneous lesions of patients with LCL caused by L. (V.) braziliensis is greater than that observed in healthy individuals, suggesting the importance of that receptor in immunopathogenesis [13].
Once [56] demonstrated by in vitro experiments that a parasite strain originating from a clinical case of ADCL was capable of activating TLR4, and that this activation was associated with LPG of the parasite. We demonstrated here that TLR4 was observed not only in the ADCL form but also in the other clinical forms (LCL and BDCL) caused by L. (L.) amazonensis, although without differences in its expression. It was moderately expressed in the central LCL form but weakly expressed in the subpolar BDCL and polar ADCL forms, an observation that could be associated with its persistent stimulation by the parasite, as both the BDCL and ADCL clinical forms are characterized by elevated parasite loads in macrophages-resulting in the saturation of TLR4 activity or its gene expression pathway due to limitations of messenger RNA transcription. That situation has been described in other models of TLR activation under conditions of prolonged exposure to lipopolysaccharide/LPS and lipoteichoic acid/ALT (bacterial PAMPs) that diminish TLR2 expression on the surfaces of mesenchymal cells [57].
Little has been observed in terms of the role of TLR9 in ACL, with exception of a single publication demonstrating that the expression of that receptor was associated with granuloma in the LCL form caused by L. (V.) braziliensis [16]. According to Abou Faker et al. [58], TLR9 has an important role in the innate immune response due to its activation of NK cells and macrophages through the production of IL-12. TLR9 expression was observed in the present work in all forms of the clinical-immunopathological spectrum of ACL, although in significantly more expressive manners in the clinical forms associated with L. (L.) amazonensis, principally when T-cell immune response was clearly suppressed, as in ADCL (CD4 + / Th2, DTH -) or BDCL (CD4 + /Th1!Th2; DTH -). This leads us to believe that, different from reports of TLR9 associated with the presence of granuloma in patients with the LCL form caused by L. (V.) braziliensis [16], TLR9 is associated with a susceptibility profile to ACL because its significant expression on the side of the spectrum associated with L. (V.) braziliensis was only observed in the BDCL clinical form, which is also associated with a partially suppressed T-cell immune response (CD4 + Th1!Th2; DTH +/-) [3,4,6,19]. It has also recently been demonstrated that L. (L.) amazonensis promotes its own survival by inducing the expression of CD200, an immunoregulatory molecule thatinhibits macrophage activation [59]. This same situation was observed inTLR2-/-, TLR3-/-and TLR 4-/-macrophages, but not in MyD88-/-, TRIF-/-and TLR9-/-macrophages. When those macrophages were treated with TLR agonists a strong increase in TLR9 activation was observed, suggesting that signaling mediated by TLR9 is required to induce CD200 by L. (L.) amazonensis[Sauter I, personal communication]. That may explain the higher interaction of TLR9 with the side of the spectrum associated with L. (L.) amazonensis, principally in those BDCL and ADCL clinical forms.
While the current analysis yielded quite satisfactory results, an interesting and somewhat surprising finding must be noted that is related to the fact that the greatest cellular reactivity with the ML form in the clinical-immunopathological spectrum of ACL caused by L. (V.) braziliensis demonstrated the lowest expressions of TLR2, 4, and 9. This seems to reflect the characteristics of the predominantly lymphoplasmacytic cellular infiltrate present in that form of the disease, with wide numerical supremacy over the macrophages that serve as target cells to be double-marked by the immunohistochemistry of TLR2, 4, and 9 (CD68 +TLR2, 4, and 9). It is therefore possible that this immunohistochemical strategy may have been influenced the weak expression of those receptors in ML form of the disease. While that clinical form shows low TLR expression, a positive correlation between TLR4 and 9 with IL-10 + was noted, which corroborates the weak IL-10 + expression in the ML/L.b form-which, as was described above, is characterized by strong CD4 + /Th1-type immune response and significant IFN-γ and TNF-α expressions [3,5,6].
Supporting information S1 Table. Antibodies used in the immunohistochemical analyses.